Vanda Pharma (VNDA) Receives Positive EMA Opinion on Hetlioz as Sleep-Wake Disorder Treatment in Blind Adults
Tweet Send to a Friend
The European Medicines Agency (EMA) has recommended granting a marketing authorization for Hetlioz (tasimelteon) to treat non-24-hour sleep-wake disorder in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
